Chapter 1
INTRODUCTION
1.1 Cancer
1.2 The Immune System
1.3 Cancer Therapy and the Immune System: Focus of the Report

Chapter 2
REVIEW OF MAJOR CANCERS TARGETED BY IMMUNOTHERAPIES AND VACCINES
2.1 Breast Cancer
Pathology
Epidemiology
Diagnosis
2.2 Colorectal Cancer
Pathology
Epidemiology
Diagnosis
2.3 Lung Cancer
Pathology
Non–Small-Cell Lung Cancer
Small-Cell Lung Cancer
Epidemiology
Diagnosis
2.4 Lymphoma
Pathology of Non–Hodgkin's Lymphoma
Epidemiology of Lymphoma
Diagnosis of Non–Hodgkin's Lymphoma
2.5 Melanoma
Pathology
Epidemiology
Diagnosis
2.6 Pancreatic Cancer
Pathology
Epidemiology
Diagnosis
2.7 Prostate Cancer
Pathology
Epidemiology
Diagnosis
2.8 Renal Cancer
Pathology
Epidemiology
Diagnosis
2.9 R&D Challenges in the Development of Cancer Immunotherapies and Vaccines

Chapter 3
CURRENT PHARMACOLOGICAL TREATMENT OPTIONS
3.1 Breast Cancer
Chemotherapy
Hormone Therapy
Targeted Therapy: Herceptin
3.2 Colorectal Cancer
Chemotherapy
Targeted Therapy: Monoclonal Antibodies
3.3 Lung Cancer
Chemotherapy (Non–Small-Cell Lung Cancer)
Targeted Therapy: Kinase Inhibitors (Non–Small-Cell Lung Cancer)
Photodynamic Therapy (Non–Small-Cell Lung Cancer)
Chemotherapy (Small-Cell Lung Cancer)
3.4 Lymphoma
Chemotherapy
Monoclonal Antibodies
Other Immuno-Based Therapies
3.5 Melanoma
Interferon
Interleukin 2
Chemotherapy
3.6 Pancreatic Cancer
Chemotherapy
Targeted Therapy: Inhibition of Epidermal Growth Factor Receptor Tyrosine Kinase
3.7 Prostate Cancer
Luteinizing Hormone-Releasing Hormone Agonists
Anti-androgens
Chemotherapy
3.8 Renal Cancer
Interferon
Interleukin-2
Targeted Therapy: Kinase Inhibitors

Chapter 4
CANCER IMMUNOTHERAPIES AND VACCINES IN DEVELOPMENT
4.1 New Approaches
Non-Specific Active Immunotherapy (Immune Modulating Agents)
Antigen Immunotherapies/Vaccines (Allogeneic)
Autologous Antigen Immunotherapies/Vaccines
Allogeneic Whole Tumor Cell Immunotherapies/Vaccines
Autologous Whole Tumor Cell Immunotherapies/Vaccines
Dendritic Cell Immunotherapies/Vaccines
DNA and Viral Vector Vaccines
4.2 Setbacks
4.3 Breast Cancer
Celldex Therapeutics
GlaxoSmithKline
Introgen Therapeutics
Oxford BioMedica
4.4 Colorectal Cancer
Celldex Therapeutics
GenVec
IDM Pharma
Intracel
Oxford BioMedica
4.5 Lung Cancer
Active Biotech
AVAX Technologies
GlaxoSmithKline
IDM Pharma
Introgen Therapeutics
Merck KGaA and Biomira
NovaRx
Pfizer and Coley Pharmaceutical
Pharmexa
Transgene
4.6 Lymphoma
Biovest International
Favrille
Genitope
Transgene
4.7 Melanoma
Antigenics
AVAX Technologies
BioVex
GenVec
GlaxoSmithKline
IDM Pharma
Medarex and Bristol-Myers Squibb
Merck KGaA
Oxxon Therapeutics
Pfizer
Progenics Pharmaceuticals
Vical
4.8 Pancreatic Cancer
Celldex Therapeutics
Cell Genesys
GenVec
GlobeImmune
Lorus Therapeutics
Pharmexa
Receptor BioLogix
4.9 Prostate Cancer
Cell Genesys
Dendreon
Northwest Biotherapeutics
Oxford BioMedica
4.10 Renal Cancer
Active Biotech
Antigenics
Argos Therapeutics
Idera Pharmaceuticals
Oxford BioMedica

Chapter 5.0
EXPERT INTERVIEWS - A VIRTUAL ROUNDTABLE
Roman M. Chicz, PhD, Senior Vice President, Research and Development
Antigenics Inc.

C. Richter King, PhD, Senior Vice President of Research
GenVec, Inc.

Arthur M. Krieg, MD, Senior Vice President, Research and Development, and Chief Scientific Officer
Coley Pharmaceutical Group

Christopher Nicodemus, MD, Senior Vice President, Research and Development
Unither Pharmaceuticals

Charles A. Nicolette, PhD, Vice President, Research and Development
Argos Therapeutics

Peter K. Working, PhD, Senior Vice President, Research and Development
Cell Genesys

Chapter 6
COMPANY DIRECTORY WITH WEB ADDRESSES

References
Index